$87.17
3.08% today
Nasdaq, Oct 20, 10:10 pm CET
ISIN
US36870G1058
Symbol
IRON

Gemini Therapeutics Inc Stock price

$89.94
+28.91 47.36% 1M
+47.78 113.30% 6M
+26.54 41.86% YTD
+39.45 78.13% 1Y
+72.74 422.91% 3Y
-14.06 13.52% 5Y
-13.06 12.68% 10Y
-13.06 12.68% 20Y
Nasdaq, Closing price Fri, Oct 17 2025
+15.58 20.95%
ISIN
US36870G1058
Symbol
IRON
Industry

Key metrics

Basic
Market capitalization
$3.1b
Enterprise Value
$2.5b
Net debt
positive
Cash
$650.0m
Shares outstanding
34.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.1
Financial Health
Equity Ratio
89.3%
Return on Equity
-24.6%
ROCE
-26.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-168.6m | $-219.3m
EBIT
$-168.8m | $-215.2m
Net Income
$-145.4m | $-199.0m
Free Cash Flow
$-135.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-52.2% | -69.2%
EBIT
-52.1% | -65.9%
Net Income
-59.8% | -81.9%
Free Cash Flow
-82.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.2
FCF per Share
$-3.9
Short interest
8.5%
Employees
125
Rev per Employee
$0.0
Show more

Is Gemini Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Gemini Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Gemini Therapeutics Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Gemini Therapeutics Inc forecast:

Buy
94%
Hold
6%

Financial data from Gemini Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
69% 69%
-
- Research and Development Expense 124 124
47% 47%
-
-169 -169
52% 52%
-
- Depreciation and Amortization 0.13 0.13
32% 32%
-
EBIT (Operating Income) EBIT -169 -169
52% 52%
-
Net Profit -145 -145
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about Gemini Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gemini Therapeutics Inc Stock News

Positive
Seeking Alpha
about 7 hours ago
Disc Medicine receives a "Strong Buy" rating due to significant progress with bitopertin for EPP and XLP treatment. IRON submitted an NDA for bitopertin under Accelerated Approval, supported by positive BEACON and AURORA phase 2 study results showing reduced PPIX and improved QoL. The company earned a rare Commissioner's National Priority Review Voucher (CNPV), potentially expediting FDA review...
Neutral
GlobeNewsWire
about 10 hours ago
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten offering of $220.0 million of shares of its common stock and, in lie...
Neutral
GlobeNewsWire
about 10 hours ago
WATERTOWN, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today outlined its recent pipeline and operational progress and strategic priorities for the rest of 2025 and 2026.
More Gemini Therapeutics Inc News

Company Profile

Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO John Quisel
Employees 125
Founded 2017
Website www.discmedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today